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Crohn’s disease (CD) is a chronic remitting and relapsing disease. Fibrostenosing complications such as intestinal
strictures, stenosis and ultimately obstruction are some of its most common long-term complications. Despite recent
advances in the pathophysiological understanding of CD and a significant improvement of anti-inflammatory
therapeutics, medical therapy for stricturing CD is still inadequate. No specific anti-fibrotic therapy exists and the
incidence rate of strictures has essentially remained unchanged. Therefore, the current therapy of established
fibrotic strictures comprises mainly endoscopic dilation as well as surgical approaches. However, these treatment
options are associated with major complications as well as high recurrence rates. Thus, a specific anti-fibrotic
therapy for CD is urgently needed. Importantly, there is now a growing body of evidence for prevention as well
as effective medical treatment of fibrotic diseases of other organs such as the skin, lung, kidney and liver. In face
of the similarity of molecular mechanisms of fibrogenesis across these organs, translation of therapeutic approaches from
other fibrotic diseases to the intestine appears to be a promising treatment strategy. In particular transforming growth
factor beta (TGF-β) neutralization, selective tyrosine kinase inhibitors, blockade of components of the renin-angiotensin
system, IL-13 inhibitors and mammalian target of rapamycin (mTOR) inhibitors have emerged as potential drug candidates
for anti-fibrotic therapy and may retard progression or even reverse established intestinal fibrosis. However,
major challenges have to be overcome in the translation of novel anti-fibrotics into intestinal fibrosis therapy,
such as the development of appropriate biomarkers that predict the development and accurately monitor therapeutic
responses. Future clinical studies are a prerequisite to evaluate the optimal timing for anti-fibrotic treatment approaches,
to elucidate the best routes of application, and to evaluate the potential of drug candidates to reach the ultimate goal:
the prevention or reversal of established fibrosis and strictures in CD patients.
Keywords: Crohn’s disease, Intestinal fibrosis, Organ fibrosis, Anti-fibrotic agentsMethods
Literature search and data selection
A comprehensive literature search was performed to assess
all relevant citations found in Embase, Medline (service of
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article, unless otherwise stated.OR ‘skin’ OR ‘lung’ OR ‘systemic nephrogenic’ AND ‘fibro-
sis’ OR ‘anti-fibrotic therapy’). Additionally, references of
cited original articles and reviews were further assessed for
relevant work. The search included studies between 1960
and 2013. These data together with the authors’ personal
experience in the field represent the basis of this review.Introduction
Crohn’s disease (CD) is a chronic remitting and relaps-
ing disease [1]. During acute flares, CD patients may
present with mainly inflammation driven symptoms
such as diarrhea, abdominal pain and weight loss [2].
However, over the long-term, the naturally progressive
disease course often culminates in stricture formation.ed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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disease develop clinically apparent strictures [3]. Stric-
tures may be subdivided into fibrotic and inflammatory
as well as mixed forms [4]. Accordingly, strictures in-
cluding inflammatory alterations might benefit from
anti-inflammatory therapy through a reduction of the
inflammation-mediated edema [5]. During the last two
decades, the therapeutic armamentarium for CD has
expanded significantly, especially with the use of anti-
tumor necrosis factor alpha (TNF-α)-based strategies
that can lead to sustained clinical response rates in a
substantial proportion of CD patients [6-8]. The suc-
cess of anti-TNF antibodies fueled the hope for altering
the natural course of CD. Most recent epidemiological
data, however, revealed that despite the establishment
of early immunosuppressive therapy in CD patients
with an increased risk of disabling disease, the fre-
quency of fibrostenosing complications did not signifi-
cantly change [9]. Thus, a specific anti-fibrotic therapy
for stricturing complications in CD patients is needed.
Despite recent advances in the pathophysiological un-
derstanding of intestinal fibrosis in CD [10,11] and in
contrast to fibrotic complications in other organs, no
specific anti-fibrotic drugs for intestinal strictures are
currently available, and all existing therapies used in
clinically apparent CD-associated stenosis are the same
that are prescribed for active luminal disease. The same
holds true for the treatment of penetrating CD, another
inflammatory bowel disease (IBD)-associated complica-
tion that is linked to impaired intestinal remodeling andFigure 1 Therapeutic strategies to modify wound healing in Crohn’s
depicted. Data derived from Embase, Medline and ClinicalTrials.gov. 6-MP, 6
cellular matrix; IL, interleukin; mAb, monoclonal antibody; TNF, tumor necrohealing. Available drugs for the treatment of fibroste-
nosing or penetrating IBD are depicted in Figure 1.
Consequently, the therapy of choice for fibrostenosing
CD, in conjunction with purely anti-inflammatory ther-
apy, comprises endoscopic dilation (ED) procedures as
well as surgical approaches, with all their associated
limitations and morbidity [12-14]. A significant number
of patients have to undergo multiple surgeries, with the
subsequent risk of developing intestinal failure. In gen-
eral, isolated strictures with a length of 4 cm or less [12]
which are devoid of ulcers [15] and are accessible by
colonoscopy [16] or double-balloon enteroscopy [17]
qualify for ED. Although ED procedures for stricturing
CD are usually technically successful, more than one
third of patients will still undergo surgery within the
next years due to insufficient response to ED [12-14]. In
addition, major complications such as bowel perfor-
ation, bleeding or infection are reported in a range of 2
to 5% [12,18]. In those CD patients where endoscopic
stricture therapy is technically not feasible or not indicated,
surgical approaches including resection and strictureplasty
are recommended. While repeated surgical bowel resec-
tions bear the risk for induction of deficiencies in gastro-
intestinal functions and ultimately may manifest short
bowel syndrome and intestinal failure, strictureplasty can
treat intestinal obstruction without reducing intestinal
length [10]. Here, the incidence of major complications in-
cluding anastomotic leakage, abscess, fistula or sepsis is
present in about 6% [19]. The recurrence rates differ be-
tween various forms of strictureplasty from 23 to 41%disease. Currently available therapies for stricturing or fistulizing CD are
-mercaptopurine; AZA, azathioprine; CD, Crohn’s disease; ECM, extra-
sis factor.
Bettenworth and Rieder Fibrogenesis & Tissue Repair 2014, 7:5 Page 3 of 16
http://www.fibrogenesis.com/content/7/1/5[20-22]. To date, no head to head comparison between ED
and strictureplasty has been performed yet. Taken together,
the insufficient therapeutic impact of currently available
anti-inflammatory drugs on stricture prevention and
treatment, the complications associated with ED or sur-
gical treatment approaches associated with high socio-
economic burden [23] as well as the high recurrence
rates of stricturing CD after procedures demand the de-
velopment and evaluation of specific anti-fibrotic agents
for stricturing CD.
Review
A basic overview of mechanisms of intestinal fibrosis
Fibrosis is defined as the accumulation of collagen-rich
extracellular matrix (ECM) in response to tissue damage
and is a common complication of multiple chronic dis-
eases [24]. Repetitive or persistent injury of the intestinal
epithelium and subsequently deeper layers of the intes-
tinal wall may initiate, perpetuate or maintain progres-
sive fibrosis [24]. With regard to the gastrointestinal
tract, acute, short-lived epithelial damage may occur as a
consequence of peptic ulcers, infectious enteritis or mild di-
verticulitis, leading to a full restitution of tissue structure.
In contrast, in CD, the gastrointestinal mucosa is exposed
to chronic remitting or continuous pro-inflammatory and
environmental stimuli. Pleiotropic mechanisms are acti-
vated like cellular stress, increased production of inflamma-
tory cytokines and chemokines such as IL-13 or IL-17
[25,26] and growth factors, such as transforming growth
factor beta 1 (TGF-β1) [27], insulin-like growth factor
(IGF) [28], platelet-derived growth factor (PDGF) [29] and
basic fibroblast growth factor (bFGF) [30]. These mediators
crucially contribute to morphological and functional alter-
ations within the bowel wall that may finally culminate in
stricture formation and loss of physiological gut functions
[31,32]. In the murine model of 2,4,6-trinitrobenzene sul-
fonic acid (TNBS)-induced colitis, inhibition of IL-13 sig-
naling by administration of small interfering RNA targeting
the IL-13-α2 receptor attenuated inflammation-associated
intestinal fibrosis [25]. This observation was corroborated
by work from the same group, indicating that TGF-β1
secretion by macrophages was increased upon IL-13
stimulation in vitro and in vivo [33]. Contractility of
isolated intestinal smooth muscle from CD patients was en-
hanced after pre-stimulation with IL-13 [34]. Additionally,
increased IL-13 transcripts were detected in muscle ex-
tracts from intestinal samples of fibrotic CD patients
compared to samples from non-inflamed areas, which
results in inhibition of fibroblast matrix metallopro-
teinase (MMP) synthesis [35]. In contrary to these
findings, there was no difference in IL-13 production
in mucosal explants and lamina propria mononuclear
cells between patients with stricturing CD and control
subjects in a different study [36].IL-17A was found to possess pro-fibrotic activity in
various cell types including cardiac fibroblasts [37], hepatic
stellate cells [38], skin fibroblasts [39] and lung epithelial
cells [40]. In addition, IL-17E was shown to increase colla-
gen production in lung fibroblasts [41]. Consistent with a
role of IL-17 in fibrosis IL-17 tissue levels were increased in
a murine model of intestinal fibrosis [26]. In human fibrotic
CD, IL-17A, but not IL-17E, was overexpressed within
tissue samples from CD strictures as compared to non-
strictured CD areas and healthy gut. IL-17 secretion from
cultured intestinal explants from strictured CD patients
was significantly increased as compared to non-strictured
CD samples. Moreover, myofibroblasts from CD strictures,
expressing the IL-17A receptor, generated more collagen
and tissue inhibitor of metalloproteinase 1 (TIMP-1) and
revealed inhibitory effects on myofibroblast migration [42].
In a clinical trial of patients with inflammatory CD,
however, blockade of anti-IL-17A by administration of
the anti-IL-17A antibody secukinumab failed to im-
prove disease activity, was associated with a high rate
of serious adverse events and had to be stopped prema-
turely since predefined criteria for futility were met
[43], indicating that further studies are necessary be-
fore using anti-IL-17-based strategies in the therapy of
intestinal fibrosis.
The core mediator in various organs for both, the initi-
ation as well as the maintenance of fibrosis is TGF-β
[44]. This growth factor is produced by a vast majority
of cells and organs in mammals and is stored in large
amounts extracellularly through chemical cross-links to
the ECM [45]. The TGF-β/Smad signaling pathway ap-
pears pivotal for the development of fibrosis [44]. Ca-
nonical intracellular signal transduction is mediated by
Smad2/3 phosphorylation by TGF-β receptor I kinase
leading to binding of Smad4. This complex translocates
into the nucleus and induces TGF-β-specific pro-fibrotic
gene expression [46]. Inhibitory members of the Smad
family such as Smad6/7 block the phosphorylation of
Smad2/3 via competition with the TGF-β receptor I
kinase [47,48].
In addition to the above mentioned mediators, the im-
balance of MMPs and TIMPs, which are physiologically
involved in maintaining a state of ‘healthy’ remodeling
and restitution, can aggravate structural changes of the
bowel wall [48,49].
Restoring the integrity of the intestinal barrier, culmin-
ating in epithelial wound closure may help to resolute
and regress fibrosis, since continuous barrier defects ap-
pear to be one potential trigger for chronic inflammation
promoting pro-fibrotic alterations. To this aim ECM-
producing mesenchymal cells are recruited. These cells
may migrate from neighboring tissue [50], originate
from circulating mesenchymal cell precursors or bone
marrow stem cell-derived mesenchymal cells [51], arise
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result from epithelial- or endothelial-mesenchymal tran-
sition (EMT and EndoMT, respectively) [52]. Recently,
the intestinal microbiota has been identified as a key pro-
fibrotic factor, as suggested by several lines of evidence:
1) Ligands to Toll-like receptor 4 (TLR4) (predominantly
from gram-negative bacteria) or TLR2 (predominantly from
gram-positive bacteria) activate NF-κB, resulting in cyto-
kine and chemokine secretion by intestinal mesenchymal
cells [53]. 2) In several experimental colitis models, mi-
crobes initiate or perpetuate gut inflammation and fibrosis,
such as in SAMP1/YitFc mice, the IL-10 knock out mice,
TNBS and peptidoglycan-polysaccharide (PG-PS)-induced
colitis [54]. 3) In humans, gene variants that affect innate
immunity, located in or near genes involved in bacterial
recognition and processing, are genetically associated to
IBD or CD as well as complicated CD courses [55].
4) Finally, circulating antibodies against microbial compo-
nents are commonly found in IBD patients and are believed
to arise from an immune response towards the luminal
microbiota. These antibodies are qualitatively and quantita-
tively associated with and predictive of a more complicated
disease phenotype including fibrostenosis [50,56-58].
Beside chronic inflammation as a major driver of in-
testinal fibrosis, inflammation-independent mechanisms
deserve closer attention. In particular, activated mesenchy-
mal cells, also referred to as disease-activated myofibro-
blasts, produce and secrete high levels of several collagen
types, such as type I, III and V [59-61] and ECM com-
pounds, such as fibronectin or tenascin C [62,63] which get
deposited, linked and subsequently form matrix networks
that can lead to increased tissue stiffness [64]. Stiffness in it-
self in the absence of inflammation activates further mesen-
chymal cells in the form of a positive feedback loop [64].
The ability of myofibroblasts to contract might further in-
crease the luminal narrowing of the intestine and contrac-
tion can be induced by factors other than inflammatory
mediators [65]. Interestingly, latent matrix-bound TGF-β1
can be activated by mesenchymal cells’ traction forces,
pulling against a mechanically resistant ECM. This leads
to a conformation change of the latency-associated pep-
tide liberating the active TGF-β1 [66].
In summary, despite different physiological functions and
unique features of the human gut, such as the high load of
microbial components, intestinal fibrosis shares patho-
logical core features with fibrosis of other organs, such as
the lung, kidney, skin or liver [24]. Consequently, anti-
fibrotic agents with proven efficacy in fibrotic disease of
these organs may represent promising candidates for stric-
turing CD and will be discussed in the following section.
Anti-fibrotic therapeutic approaches in other organs
Commonly used drugs for the anti-inflammatory therapy
of CD have been observed to possess at least minor anti-fibrotic properties in other organs. For example, cortico-
steroids were found to decrease pro-collagen expression
in vivo and in vitro [67] as well as to inhibit collagenase
activity [68]. Corticosteroids show some effect in retro-
peritoneal fibrosis [69], systemic sclerosis [70] and idio-
pathic pulmonary fibrosis (IPF) [71]. In contrast, human
intestinal myofibroblasts respond to corticosteroids with
enhanced pro-collagen expression upon dexamethasone
stimulation [72]. In stricturing CD, small case series report
variable therapeutic success rates of intralesional steroid in-
jection [73]. The long-term systemic administration of
corticosteroids in CD, however, is obsolete due to severe
and pleiotropic side effects. Azathioprine, one of most
commonly prescribed immunosuppressive drugs for main-
tenance of remission in CD patients, is beneficial in the
treatment of retroperitoneal fibrosis [74] and fibrotic pul-
monary disease [75,76]. In CD patients, azathioprine may
delay postoperative, fibrotic complications [77], however,
the early use of immunosuppressive treatment regimens
does not reduce the occurrence of intestinal strictures and
frequency of surgical interventions in the long-term [9,78].
TNF-α is a critical cytokine in the pathogenesis of IBD and
to date four anti-TNF antibodies have shown clinical effi-
cacy as anti-inflammatory agents [79-82] and are available
for clinical use. Several reports from liver fibrosis [83], pul-
monary fibrosis [84] and systemic sclerosis [85] suggest an
anti-fibrotic effect of anti-TNF treatment. This could be ex-
plained by TNF-α-mediated myofibroblast activation, in-
creased collagen production and TIMP-1 expression as
well as inhibition of MMP-2 activity and collagen degrad-
ation [86]. In contrast, human intestinal myofibroblasts
from CD patients show increased expression of TIMP-1
and decreased collagen production upon exposure to
infliximab [87]. After initially conflicting data in patients
with CD with a possible pro-fibrotic effect of anti-TNF
therapy in vivo, recent data revealed no link between anti-
TNF administration with intestinal stricture formation
[88]. Information derived from a small retrospective study
points towards at least a partial amelioration of stricture
formation with anti-TNF therapy [89] and anti-TNF treat-
ment may delay the time to surgery in CD [90].
In daily clinical practice, most CD patients present with
established strictures, representing the end-stage of the fi-
brotic process, and most clinicians see this scenario as an
inevitable progression to a likely surgical intervention.
This does not have to be so, as the theoretical and prac-
tical feasibility to stop or even reverse intestinal fibrosis is
supported by the observation that tissue alterations in ex-
perimental models of intestinal fibrosis disappear after
elimination of the pro-fibrotic stimulus [54]. No thera-
peutic medical strategy for pre-existing intestinal stric-
tures exists at the moment, but this clinical scenario could
greatly improve by looking at existing knowledge derived
from other organ systems.
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heart or skin can be grouped into strategies modulating
growth factors, inflammation or oxidative stress, intra-
cellular enzymes, and ECM production or assembly
(Figure 2). We herein provide a summary of currently
available experimental anti-fibrotics that have been
tested for indications outside of the intestine. We se-
lected promising mechanisms and agents that could be
applicable to stricture therapy of CD in the near future
and describe them in greater detail.
Growth factors
Feasibility of TGF-β1 blockade to treat fibrotic diseases
has been shown in IPF. In this condition, TGF-β is driving
fibrotic alterations and epithelium-dependent fibroblast
activation [44]. In murine models of IPF, antagonizing
TGF-β action via Tβ-RII (as a ligand decoy), P144, an in-
hibitor of TGF-β activity, or P17, an anti-TGF-β peptide,
resulted in potent anti-fibrotic effects [91-93]. In human
IPF patients, two phase III trials have shown that treat-
ment with pirfenidone, an agent inhibiting TGF-β activity
and p38 mitogen-activated protein kinase (MAPK) signal-
ing, improved pulmonary function [94,95]. Pirfenidone is
expected to be approved for IPF in Europe soon [96]. An-
other example for the potential of anti-TGF-β-based strat-
egies is scleroderma, a disease characterized by enhanced
expression of TβRI and TβRII in fibroblasts leading to in-
creased collagen I production and ECM deposition in the
skin and internal organs [97]. Topical treatment withFigure 2 Pipeline for therapeutic strategies to alter and improve fibrosis
organ. Agents are classified based on their mode of action. Data derived from E
connective tissue growth factor; ECM, extracellular matrix; HIF, hypoxia inducible
monoclonal antibody; SAP, serum amyloid P component; TGF-β, transforming gP144 has shown efficacy in patients with systemic scler-
osis, and multiple trials with this agent are currently on-
going. Fresolimumab (GC1008) is a humanized antibody
targeting anti-TGF-β1,2 and 3 and was recently evaluated
in a phase I trial in patients with treatment-resistant
primary focal segmental glomerulosclerosis [98]. The hu-
manized αVβ6 integrin-blocking antibody STX-100, which
inhibits the activation of latent TGF-β on epithelial cells,
is currently being examined in a phase II trial in IPF pa-
tients [24,99]. Comparable results have been reported
from kidney fibrosis: preclinical in vitro and in vivo studies
indicate an anti-fibrotic activity using anti-TGF-β anti-
bodies, soluble TGF-β receptor, blockade of TGF-β
activation by decorin, a small-molecule inhibitor of
TGF-β receptors [100], administration of inhibitory
protein Smad7 [101] and thrombospondin-1 (THBS-1)
blocking agent inhibiting TGF-β activation [102]. In
human patients with focal segmental glomerulosclerosis, a
phase I trial with fresolimumab revealed promising results
[98]. Moreover, hepatic growth factor, acting as an inhibitor
of Smad2/3 translocation in fibroblasts [103] was observed
to mediate anti-fibrotic effects in experimental models of
renal and liver fibrosis but was also associated with an in-
creased risk of hepatocellular carcinoma [104]. Substrate
specificity of therapeutics needs to be taken into consider-
ation as well. In an experimental model of scleroderma,
blocking activin receptor-like kinase 5 (ALK5), which is in-
volved in phosphorylation of Smad2/3, leads to decreased
fibroblast activation. However, ALK5 blockade in clinicalin organs other than the intestine. Each color represents a particular
mbase, Medline and ClinicalTrials.gov. CCL2, chemokine ligand 2; CTGF,
factor; IL, interleukin; JAK, janus kinase; JNK, c-Jun N-terminal kinase; mAb,
rowth factor beta; VIP, vasoactive intestinal peptide.
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reactivity with other kinase inhibitors [105].
In addition to the Smad-signaling cascade, non-Smad
pathways comprising TGF-β1 activated MAPKs and sev-
eral tyrosine kinases have been targeted for anti-fibrotic
actions. For example, c-Abelson (c-Abl), a component of
the Bcr-Abl oncogene, can be effectively blocked by se-
lective tyrosine kinase inhibitors such as imatinib. This
agent inhibits PDGF as well and thus potentially regu-
lates fibroblast proliferation and transformation [106].
Despite promising results from in vitro and in vivo stud-
ies, to date limited experience with tyrosine kinases in
human fibrotic diseases is available [107,108]. Of note,
novel tyrosine kinase inhibitors such as nilotinib and
dasatinib mediate dose-dependent decreases in ECM
production and reveal even greater efficacy as compared
to that of imatinib [109], while being well tolerated by
the patients [110]. In contrast to TGF-β1, other mem-
bers of the TGF family such as TGF-β3 possess anti-
fibrotic properties. Avotermin is a recombinant bioactive
human TGF-β3 that has been tested for treatment of
dermal scars and significantly reduces the scar size by
intradermal injection therapy [111]. In addition, further
growth factors such as serum amyloid P (SAP) have
been proven effective in experimental models [112,113]
of fibrosis and have already entered phase I clinical trials
in human patients [114].
The scientific rationale to target TGF-β signaling in
stricturing CD comes from in vitro as well as in vivo ob-
servations. For example, intestinal TGF-β overexpression
in mice leads to colonic fibrosis and obstruction [27],
while disruption of the TGF-β/Smad signaling cascade
protects animals from intestinal fibrosis [115]. In human
tissue samples from colonic CD strictures, TGF-β and its
receptors as well as pSmad2/3 expression are increased,
while Smad7 expression was significantly reduced [116]. Al-
though targeting TGF-β signaling for fibrotic diseases has a
strong scientific rationale, it has to be taken into account
that this growth factor is not only crucially involved in
fibrogenesis but additionally functions as a key regulator of
cellular processes including differentiation, proliferation,
transformation, tumor suppression as well as immunoregu-
lation and its actions may be context-dependent [96,117].
For example, TGF-β1-deficient mice develop severe multi-
organ inflammation and expire by 5 weeks of age [118,119].
This outcome occurs even under germ-free conditions
[120] and is mediated by CD4+ T cells [121]. Similarly, tar-
geted deletion of Smad2 and Smad4 is associated with early
death in mice [122,123]. Furthermore, administration of
metelimumab, a monoclonal antibody against TFG-β1, in
human systemic sclerosis patients was associated with sig-
nificantly more serious adverse events than placebo treat-
ment including musculoskeletal pain, progression of skin
involvement and death [124]. Possible side effects duringanti-TGF-β therapy would have to be carefully monitored,
in particular in case of pre-existing inflammation. There-
fore, neutralizing TGF-β 1 in vivo, as an anti-fibrotic ap-
proach in CD may be highly problematic, as this may
actually lead to disease exacerbation given the potent
anti-inflammatory and immunoregulatory properties of
this cytokine.
HMG-CoA reductase inhibitors
HMG-CoA reductase inhibitors were developed with the
intention to decrease cholesterol levels. More recently,
they were found to mediate anti-inflammatory as well as
anti-fibrotic effects in vitro [125], including decreased
proliferation of mesangial cells, lower fibronectin as well
as type IV collagen expression and decreased secretion
of TGF-β1 and connective tissue growth factor (CTGF)
[126-128]. Corroborating these in vitro findings, HMG-
CoA reductase inhibitors revealed various anti-fibrotic
effects in murine models of nephropathy and fibrosis
[126,127]. In CD patients, HMG-CoA reductase inhibitor
atorvastatin was shown to mediate anti-inflammatory ef-
fects such as inhibition of T cell recruitment via reduced
CXCL10 levels [129] and reduce surrogate inflammatory
markers such as calprotectin, C-reactive protein and TNF-
α expression [130]. Furthermore, it was demonstrated that
simvastatin reduced TGF-β1 expression in human fibro-
blasts by inhibition of Smad3 phosphorylation [131] lead-
ing, together with induced apoptosis in fibroblast and
myofibroblasts, to a significant amelioration of experi-
mental fibrosis [132]. In addition, mesenchymal cells
isolated from patients with radiation-induced intestinal
fibrosis respond to pravastatin treatment with signifi-
cantly decreased production of fibronectin and type-1
collagen through Rho-/ROCK-dependent reduction of
CTGF expression [133]. Nevertheless, the exact anti-
fibrotic potential of statin treatment in stricturing CD
still needs to be defined by the use of hard clinical end-
points, but this drug class has an already established
safety profile for routine clinical use and could serve as
a potential anti-fibrotic treatment approach.
Renin-angiotensin system (RAS) modulators
Angiotensin II (AT II) is the major mediator of the
renin-angiotensin system (RAS). AT II may increase ECM
accumulation through plasminogen activator inhibitor-1-
mediated decrease of MMPs and enhance TGF-β1 produc-
tion in cardiac and renal fibrosis [134,135]. The impact of
AT II can also be observed in liver fibrosis. In hepatic stel-
late cells, AT II induces contraction and proliferation ac-
companied by increased collagen and TGF-β expression
[136]. Accordingly, progression of liver fibrosis in hepatitis
C virus positive patients is significantly decreased after
treatment with angiotensin-converting enzyme inhibitors
[137]. AT II is crucially involved in the manifestations of
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and EMT resulting in enhanced ECM production [138],
and inhibition of AT II using angiotensin-converting en-
zyme (ACE) inhibitors or blocking agents towards the AT I
receptor has emerged as a therapeutic approach to slow
down renal disease progression [139] and revealed anti-
fibrotic actions in the lung, heart and liver [140-143]. Inter-
estingly, all components of the RAS have been detected in
the human colonic mucosa [144] and AT II is increased in
the mucosa of CD patients [145]. In vivo administration of
the ACE inhibitor enalaprilate has been proven to reduce
weight loss and histological damage in murine dextran sul-
fate sodium (DSS)-induced colitis [146]. ACE inhibitor
treatment was also effective in spontaneous colitis of IL-10-
deficient mice [147] and this finding has been confirmed by
other studies [148,149].
Of note, through its AT1 receptor, AT II enhances the
expression of CTGF, and administration of AT II inhibi-
tors and AT1 receptor antagonists significantly amelio-
rates or reverses fibrotic alterations in experimental
colitis reflected by reduced collagen amounts and TGF-
β1 mRNA levels [150,151]. Existing preclinical data in
IBD combined with clinical trials from the liver and kid-
ney make RAS modulation a promising future approach
for CD-associated fibrosis.
Inflammation modulators
Pro-inflammatory cytokines contributing to the patho-
genesis of IBD could also be involved in the develop-
ment of intestinal fibrosis in CD. For example, IL-1
modulates myofibroblast activation, chemokine produc-
tion, MMP secretion [152] and is involved in EMT in-
duction [153]. IL-6 is known to regulate TGF-β and
TGF-βR2 expression as well as fibroblast proliferation
[154,155] and is strongly upregulated in serum and tis-
sue samples from CD patients [156]. IL-4 and IL-13 rep-
resent pivotal mediators of immune activation and T
helper cell 2 responses are crucially involved in the de-
velopment of intestinal fibrosis in vivo. IL-13 mediates,
through binding to its IL-13Rα, an increased production
of TGF-β and is a key player in the initiation of fibrotic
alterations in the intestine [25]. Confirmatively, antagon-
ism of IL-13 is effective to prevent fibrosis development
in experimental colitis [33,157]. In addition, several IL-
13 antibodies such as lebrikizumab, tralokinumab and
QAX576 as well as the anti-TNF antibody etanercept
and the immunomodulatory drug thalidomide are cur-
rently being evaluated for their anti-fibrotic potency in
liver fibrosis and pulmonary fibrosis [24,158-160].
The process of inflammation and fibrosis are likely to
be intertwined through angiogenesis and lymphangio-
genesis. Increased levels of factors implicated in angio-
genesis have been documented in IBD patients, such as
vascular endothelial growth factor A (VEGF-A) [161]. Ata cellular level, PDGF increases proliferation and migra-
tion of fibroblasts and myofibroblasts [46]. In the human
intestine, PDGF facilitates ECM deposition and is upreg-
ulated in inflamed colonic tissue specimen of CD pa-
tients [29]. Experience with blocking these agents in
other fibrotic diseases exist. In a phase II trial, combined
blockade of VEGF, PDGF and bFGF by the indolinone
derivative BIBF 1120 tends to decrease the development
of human IPF [162]. Critical for the future use of inflam-
mation modulators in the therapy of CD-associated fi-
brosis will be the quality, quantity and the timing of the
approach because all of the above mediators act at dif-
ferent times throughout the disease course, in differing
combinations and quantities [163]. Additionally, all of
the above molecules interact with each other and block-
ing a single cytokine at a specific time might not be suf-
ficient for effective anti-fibrotic therapy.
Extracellular matrix modulators
The imbalance between deposition and degradation of
ECM in fibrotic disease is a logical target for anti-fibrotic
treatment approaches. Stimulation of MMPs as central reg-
ulators of ECM disassembly were expected to reverse fi-
brotic alterations, however, clinical studies in patients with
nephrosclerosis failed to show efficacy [164]. Likewise, de-
pletion of TIMP should decrease fibrotic changes, but no
amelioration of renal fibrosis was observed following TIMP
inhibition in mice [165]. With regard to the intestine, there
is growing evidence for MMPs as a regulator of intestinal
barrier function and mucosal defense [166], indicating
pleiotropic functions of this molecular group in addition to
purely matrix regulation. For example, serum MMP-9
levels correlate with disease activity in pediatric CD patients
[167] and may be used as a biomarker to follow the course
of disease in adult CD patients as well [168,169]. Colonic
tissue expression of MMP-1, MMP-2, MMP-3 and MMP-9
was significantly increased in samples from inflamed mu-
cosa as compared to non-inflamed mucosal samples [170].
Increased MMP-9 expression in inflamed tissue colonic
specimen from CD patients seems to be associated with de-
creased likelihood of disease recurrence [171]. Finally, in
mucosa specimen overlaying colonic strictures in CD pa-
tients, MMP-3 and MMP-12 expression was significantly
reduced [116]. Thus, MMPs need to be further and care-
fully investigated as possible targets for anti-fibrotic treat-
ment in as well as outside of the intestine and are not yet
ready for prime time.
Intracellular enzymes and receptors
The mammalian target of rapamycin (mTOR) protein is a
serine/threonine protein kinase that consists of several
complexes among which mTOR complex 1 regulates pro-
tein synthesis, proliferation as well as fibrotic actions [46].
mTOR inhibitors possess direct anti-fibrotic properties by
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ducing pro-fibrotic cytokine expression, including IL-4, IL-
6, IL-13, IL-17, TGF-β1 as well as type I and III collagen
[172,173]. Efficacy of mTOR inhibitors have been demon-
strated in numerous fibrotic disorders of the skin, lung,
kidney and liver [46]. With regard to CD, a randomized,
double-blind clinical trial found that everolimus was as ef-
fective as azathioprine to achieve steroid-free remission in
138 patients with active CD [174]. Additionally, there are
two case reports indicating that mTOR inhibitors sirolimus
and everolimus are able to induce remission in refractory
CD [175,176]. Given the fact that mTOR inhibitors possess
anti-fibrotic as well as immunosuppressive effects, this class
of drug appears to be promising for intestinal fibrosis ther-
apy, however, the definitive therapeutic potential for intes-
tinal fibrosis remains to be defined yet.
Peroxisome proliferator-activated receptor gamma
(PPAR-γ) is a nuclear receptor that modulates gene expres-
sion and is involved in various physiological and patho-
logical processes including inflammation and fibrosis [177].
After stimulation with specific ligands, PPAR-γ directly
antagonizes Smad3 or reduces CTGF expression [178].
PPAR-γ agonists are able to improve experimental fibrosis,
while PPAR-γ selective antagonists abolish anti-fibrotic
actions [179,180]. Given the fact that CTGF is a key down-
stream effector of TGF-β on connective tissue cells, FG-
3019, a humanized antibody targeting CTGF, has beenFigure 3 Compounds used as anti-fibrotic therapies in other organs an
pathway. Compounds are depicted in red, indicating their mechanism of actio
connective tissue growth factor; ECM, extracellular matrix; HGF, hepatocyte gr
Inhibitor; IL, interleukin; MAPK, mitogen-activated protein kinase; mTOR, mam
receptor; SMAD, small mothers against decapentaplegic; TGF, transforming grdeveloped and successfully passed phase I trials in several
fibrotic disorders and recently entered phase II studies [24].
In the human intestine, PPAR-γ has been detected in the
colonic mucosa and has been identified as a mediator
of established anti-inflammatory drugs such as 5-ASA
[177,181]. The future role of PPAR-γ agonists as a pos-
sible target for anti-fibrotic treatment in stricturing
CD is promising, given the combined action against
inflammation and fibrosis and its well-defined mechanism
of action. Furthermore, other drug candidates such as
endothelin A receptor antagonist bosentan have shown
promising results in patients with IPF and renal interstitial
fibrosis and deserves further investigation [182,183].
A summary of compounds used as anti-fibrotic therapies
in other organs and their mode of action is depicted in
Figure 3. Anti-fibrotic clinical trials of major interest are
shown in Table 1.
Challenges and future outlook
The most efficient anti-fibrotic treatment approach still
remains the elimination of the primary cause of intes-
tinal injury, which would mean nothing less than curing
CD. However, since a magic bullet for CD is not and will
most likely not be available in the near future, clinical
evaluation and optimization of anti-fibrotic drug candi-
dates for stricturing CD is a justifiable and promising
treatment strategy.d their mode of action. The blue boxes represent a major profibrotic
n. Abs, antibodies; ALK, activin receptor-like kinase; AT, angiotensin; CTGF,
owth factor; HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme A; Inh,
malian target of rapamycin; PPAR, peroxisome proliferator-activated
owth factor.





Type of trial Study drug Mode of action Outcome measures
Growth factors Noble [95] Lung 779 RCT, phase III Pirfenidone Inhibition of TGF-β Increased FVC in IPF
Trachtman [98] Kidney 16 Open-label, phase I Fresolimumab Antibody targeting all
isoforms of TGF-β
Safety, pharmacokinetics
Ferguson [111] Skin 223 RCT, phase I/II Avotermin Antibody targeting
TGF-β3
Acceleration and permanent improvement
in dermal scaring
Dillingh [114] Lung 29 RCT, phase I rhSAP Substitution of SAP Reduction in SAP levels and circulating
fibrocytes in healthy control and
IPF patients
Oxidative stress Raghu [158] Lung 88 RCT, phase II Etanercept Blockade of TNF Physiological and functional decrease in
disease progression in IPF
Corren [159] Lung 219 RCT, phase II Lebrikizumab Antibody targeting IL-13 Improved lung function in asthmatic
patients
Horton [160] Lung 23 RCT, phase III Thalidomide Anti-angiogenic and
anti-inflammatory
Improvement of cough and respiratory
quality of life in IPF
Intracellular enzymes
and receptors
Richeldi [162] Lung 432 RCT, phase II BIBF 1120 Tyrosine kinase
inhibitor
Tendency towards reduced decline of lung
function in IPF
Daniels [108] Lung 119 RCT, phase II/III Imatinib Tyrosine kinase
inhibitor
No effect on survival and lung function
ECM and other Couluris [140] Lung 20 Uncontrolled, interventional
study, phase II
Losartan AT1 antagonist Stabilization of lung function in IPF
el-Agroudy [142] Kidney 162 RCT, phase II Losartan AT1 antagonist Decreased TGF-β1 plasma levels and
proteinuria in renal interstitial fibrosis




Reduced skin thickening in systemic sclerosis
Diez [141] Heart 34 Uncontrolled, phase II Losartan AT1 antagonist Decreased myocardial collagen content and
left ventricular chamber stiffness in
hypertensive patients
De [143] Liver 39 RCT, phase II Losartan AT1 antagonist Reduction of portal pressure in patients
with liver cirrhosis
King [183] Lung 616 RCT Bosentan Endothelin receptor
antagonist
Improvement of FVC and diffusing capacity
in IPF
AT1, angiotensin II receptor antagonist subtype 1; CXCL, CXC ligand; ECM, extracellular matrix; FVC, forced vital capacity; IL, interleukin; IPF, idiopathic pulmonary fibrosis; RCT, randomized controlled trial; SAP, serum
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treatment is premature and multiple obstacles have to
be overcome to make use of the above described media-
tors and mechanisms.
First, the ideal anti-fibrotic drug should target some-
thing uniquely expressed in a specific fibrotic compli-
cation in a particular organ and should not display any
systemic side effects. This is particularly true in case of
concomitant injury elsewhere in the body. To date,
however, no specific target for intestinal fibrosis or
other fibrotic disease has been identified, which sup-
ports the hypothesis that mechanisms of fibrosis are
shared between different organs.
Second, the optimal timing to commence anti-fibrotic
treatment is of utmost importance to CD patients, how-
ever, is not defined yet. It is obvious that an early use of
anti-fibrotics is expected to be associated with a better out-
come in patients prone to this complication. Pre-existing fi-
brosis and concomitantly increased tissue stiffness can
perpetuate fibrosis even in the absence of inflammation.
Data from experimental fibrosis seems to confirm that
there might be a critical point in evolution of fibrosis when
the progress becomes irreversible [184]. Therefore, an early
treatment with anti-fibrotics at the same time of anti-
inflammatory agents might be mandatory in human CD pa-
tients [185]. Unique to CD is a fistulizing disease process
and this complication needs to be kept in mind when using
drugs inhibiting tissue remodeling because this could theor-
etically promote fistulizing disease. However, timing may
not be simply based on the disease duration, since up to
50% of CD patients present with stricturing or penetrating
disease at the time of first diagnosis [186].Figure 4 A suggested path to more efficient translation of new disco
Friedman et al. [24]. IBD, inflammatory bowel disease.Third, a patient-tailored anti-fibrotic treatment ap-
proach necessitates the identification of biomarkers to
enable individual risk stratifications for stricturing dis-
ease and to follow the individual evolution of fibrosis. As
opposed to other organs, such as liver [187,188] or lung
[159], regrettably, no clinically useful biomarkers for
stricturing CD as well as for assessment of therapeutic
response are available yet. Promising approaches include
serology [189,190] or imaging techniques [191-196], but
the currently used tools only detect endpoints based on
clinical findings of possible CD fibrosis and hence are
not accurate.
Fourth, the best route of application for anti-fibrotic
agents in stricturing CD has to be elucidated. In line
with the beneficial effects of systemic administration of
anti-fibrotics in other organs [24], intravenous or oral
application may be appropriate. The CD intestine offers
the advantage of potential local therapy as a large propor-
tion of strictures is accessible via endoscopy. Intralesional
injection or topical application of anti-fibrotics is a valid
and practical therapeutic option, as shown by steroid
[197] or infliximab application [198]. This approach may
be associated with fewer side effects as compared to sys-
temic administration.
Finally, a general limitation to evaluating potential
anti-fibrotic agents is the long-lasting evolution of fi-
brotic complications in patients with CD requiring clin-
ical trials of long duration and large patient populations,
making them very expensive and impractical [24].
It is unclear and in the realm of speculation, which of
the reviewed drugs has the highest potential for success
as an anti-fibrotic treatment in CD. Combining drugsveries to Crohn’s disease-associated fibrosis. Adapted from
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such as HMG-CoA reductase inhibitors, mTOR inhibi-
tors or inhibitors of the angiotensin system, could serve
as a starting point. Given the effect of most substances
on a reduction of TGF-β1 proper precaution needs to be
taken for carefully monitoring intestinal inflammation.
Novel drug delivery systems, such as the Multi Matrix
System (MMX®), allowing oral administration of a com-
pound with the substance being released in a defined
area of the gastrointestinal tract (such as the terminal
ileum) can circumvent systemic side effects, such as
hypotension for angiotensin blockade.
To move forward with specific anti-fibrotic therapies
in the future we need to focus on identifying mecha-
nisms of fibrogenesis and to develop new and better ani-
mal models for this disease (Figure 4). What, however, is
badly missing is the availability of biomarkers for natural
history and response to therapy that are readily available
and easy to measure. Only through utilization of these
markers will the field be able to design clinical studies of
reasonable length and sufficient patient number, reflected
in affordable budgets that put our ability for testing anti-
fibrotic therapies within reach.
Conclusions
Stricturing CD is still an unresolved problem with
strong implications for the patients and a high socioeco-
nomic burden due to frequent hospitalizations and
surgery [23]. Despite recent advances in the patho-
physiological understanding of fibrosis and significant
expansion of the anti-inflammatory armamentarium
over the last few decades, the occurrence of intestinal
strictures in CD patients did not significantly change.
To date, effective therapeutic approaches for stricturing
CD are limited to ED or surgical interventions. The data
presented in this review highlight the pleiotropic anti-
fibrotic actions that have been observed with the use of
numerous agents in fibrotic complications of the skin,
the lung and the kidney. Thus, it is justified to propose
further evaluation of these drug candidates in clinical
trials for the management of intestinal fibrosis. How-
ever, previous establishment of non-invasive biomarkers
to assess the degree of fibrosis, to monitor fibrotic evo-
lution and to predict therapeutic response, combined
with the development of imaging techniques to quantify
intestinal fibrosis, appear to be essential pre-requisites
for individual risk stratification and proper design of
clinical trials.
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